Pharmacokinetic and Pharmacodynamic Properties of Cinacalcet (KRN1493) in Chinese Healthy Volunteers: A Randomized, Open-label, Single Ascending–dose and Multiple-dose, Parallel-group Study-Reference-Cited by-同舟云学术

Pharmacokinetic and Pharmacodynamic Properties of Cinacalcet (KRN1493) in Chinese Healthy Volunteers: A Randomized, Open-label, Single Ascending–dose and Multiple-dose, Parallel-group Study

Published:2016-02 Issue:2 Volume:38 Page:348-357
ISSN:0149-2918
Container-title:Clinical Therapeutics
language:en
Short-container-title:Clinical Therapeutics

Author:

Liu Hongzhong,Wang Hongyun,Liu Tao,Jiang Ji,Chen Xia,Gao Feng,Hu Pei

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmacology

Reference25 articles.

1. Hyperparathyroidism;Fraser;Lancet,2009

2. Development and progression of secondary hyperparathyroidism in chronic kidney disease: lessons from molecular genetics;Goodman;Kidney Int,2008

3. Renal bone disease;Sprague;Curr Opin Endocrinol Diabetes Obes,2010

4. Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study;Young;Kidney Int,2005

5. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis;Block;J Am Soc Nephrol,2004

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparative effects of calcitriol and calcimimetic on bone health in renal insufficiency;The FASEB Journal;2024-06-07

2. Oral cinacalcet administration decreases serum ionized calcium and parathyroid hormone concentrations in healthy dogs;Journal of Veterinary Pharmacology and Therapeutics;2024-04-02

3. Pharmacokinetics, Pharmacodynamics, and Safety of Evocalcet (KHK7580), a Novel Calcimimetic Agent: An Open-Label, Single- and Multiple-Dose, Phase I Trial in Healthy Chinese Subjects;Drug Design, Development and Therapy;2024-02

4. Development and validation of an LC-MS/MS method by one-step precipitation for cinacalcet in human plasma;Heliyon;2023-06

5. Physiologically-Based Pharmacokinetic Models of CYP2D6 Substrate and Inhibitors Nebivolol, Cinacalcet and Mirabegron to Simulate Drug–Drug Interactions;European Journal of Drug Metabolism and Pharmacokinetics;2022-07-15